Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial

Elter, Thomas; Gercheva-Kyuchukova, Liana; Pylylpenko, Halyna; Robak, Tadeusz; Jakšić, Branimir; Rekhtman, Grigoriy; Kyrcz‐Krzemień, Sławomira; Vatutin, Mykola; Wu, Jingyang; Sirard, Cynthia A.; Hallek, Michael; Engert, Andreas

doi:10.1016/s1470-2045(11)70242-x

Cited by 81 publications

(48 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Combination therapies using two or more therapeutic agents targeting specific pathways can synergistically eradicate cancer and halt tumor growth, however certain combinations may be more detrimental or quality of life may decrease despite an increase in survival time [65,66]. There are currently hundreds of combination therapies undergoing clinical evaluation, and Table 1 lists several examples of recently completed Phase III clinical trials [67][68][69][70][71][72][73][74][75][76][77]. Targeting multiple constituents within a single pathway may allow for a maximum inhibition of that particular signaling network, possibly even a complete shutdown [78,79].…”

Section: Simultaneously Targeting Major Oncogenic Pathways By Multiplmentioning

confidence: 99%

“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

Kemp

Shim

Heo

et al. 2016

Advanced Drug Delivery Reviews

423

258

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oThe dynamic and versatile nature of diseases such as cancer has been a pivotal challenge for developing efficient and safe therapies. Cancer treatments using a single therapeutic agent often result in limited clinical outcomes due to tumor heterogeneity and drug resistance. Combination therapies using multiple therapeutic modalities can synergistically elevate anti-cancer activity while lowering doses of each agent, hence, reducing side effects. Co-administration of multiple therapeutic agents requires a delivery platform that can normalize pharmacokinetics and pharmacodynamics of the agents, prolong circulation, selectively accumulate, specifically bind to the target, and enable controlled release in target site. Nanomaterials, such as polymeric nanoparticles, gold nanoparticles/cages/shells, and carbon nanomaterials, have the desired properties, and they can mediate therapeutic effects different from those generated by small molecule drugs (e.g., gene therapy, photothermal therapy, photodynamic therapy, and radiotherapy). This review aims to provide an overview of developing multi-modal therapies using nanomaterials ("combo" nanomedicine) along with the rationale, up-to-date progress, further considerations, and the crucial roles of interdisciplinary approaches.

show abstract

Section: Simultaneously Targeting Major Oncogenic Pathways By Multiplmentioning

confidence: 99%

“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

Kemp

Shim

Heo

et al. 2016

Advanced Drug Delivery Reviews

423

258

View full text Add to dashboard Cite

show abstract

“…Of those studies, seventeen were nonrandomized [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] and six were randomized [33][34][35][36][37][38] . The studies included a total of 27 treatment arms and a mean of 118 patients (minimum 30, maximum 724).…”

Section: Descriptive Analysesmentioning

confidence: 99%

Relationship between Progression-Free Survival and Overall Survival in Chronic Lymphocytic Leukemia: A Literature-Based Analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Patients received 4 monthly courses of the FA regimen (fludarabine, 30 mg/m2 iv; alemtuzumab, 30 mg iv, days 1-3) [19,20]. Responding patients with no evidence of residual disease at the molecular level (mol-CR) underwent a peripheral blood stem cell (PBSC) mobilization only, while patients with residual disease (partial response, PR; complete response, CR; cytometric complete response, cy-CR) underwent post-remissional therapy.…”

Section: Study Treatmentmentioning

confidence: 99%

“…Results from a single-group phase 2 study by Elter et al suggested that the fludarabine and alemtuzumab (FA) combination could improve the outcome of patients with relapsed or refractory CLL [19]. The same authors confirmed the efficacy of the FA combination in a study where this regimen was compared with fludarabine monotherapy in patients with relapsed or refractory CLL [20].…”

Section: Introductionmentioning

confidence: 98%

Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

et al. 2014

View full text Add to dashboard Cite

a b s t r a c tIn 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab ® ) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.

show abstract

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial

Cited by 81 publications

References 20 publications

“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

Relationship between Progression-Free Survival and Overall Survival in Chronic Lymphocytic Leukemia: A Literature-Based Analysis

Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Contact Info

Product

Resources

About